Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $236.00

by · The Markets Daily

Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its price target boosted by B. Riley from $194.00 to $236.00 in a research note released on Tuesday,Benzinga reports. B. Riley currently has a neutral rating on the biopharmaceutical company’s stock. B. Riley also issued estimates for Madrigal Pharmaceuticals’ Q4 2024 earnings at ($3.86) EPS, FY2024 earnings at ($23.09) EPS, Q1 2025 earnings at ($3.34) EPS, Q2 2025 earnings at ($3.09) EPS, Q3 2025 earnings at ($2.86) EPS, Q4 2025 earnings at ($2.46) EPS, FY2025 earnings at ($11.72) EPS, FY2026 earnings at $15.22 EPS and FY2027 earnings at $32.42 EPS.

MDGL has been the subject of a number of other research reports. StockNews.com raised shares of Madrigal Pharmaceuticals to a “sell” rating in a research note on Saturday, October 12th. Evercore ISI cut their price target on shares of Madrigal Pharmaceuticals from $405.00 to $360.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Madrigal Pharmaceuticals in a report on Friday, October 11th. UBS Group upped their price objective on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Finally, JMP Securities lifted their target price on Madrigal Pharmaceuticals from $381.00 to $385.00 and gave the company a “market outperform” rating in a report on Tuesday, July 16th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $347.33.

View Our Latest Stock Analysis on MDGL

Madrigal Pharmaceuticals Stock Up 4.9 %

Shares of NASDAQ:MDGL opened at $354.85 on Tuesday. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $7.74 billion, a P/E ratio of -14.15 and a beta of -0.46. Madrigal Pharmaceuticals has a 52-week low of $133.99 and a 52-week high of $368.29. The stock’s fifty day simple moving average is $234.44 and its 200-day simple moving average is $245.87.

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share for the quarter, beating the consensus estimate of ($6.94) by $2.02. The business had revenue of $62.18 million during the quarter, compared to analyst estimates of $34.60 million. During the same quarter last year, the firm posted ($5.34) earnings per share. As a group, equities research analysts forecast that Madrigal Pharmaceuticals will post -25.19 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Madrigal Pharmaceuticals news, Director Richard S. Levy sold 5,000 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $300.94, for a total value of $1,504,700.00. Following the completion of the sale, the director now owns 11,012 shares of the company’s stock, valued at $3,313,951.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO William John Sibold sold 6,363 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $243.83, for a total value of $1,551,490.29. Following the completion of the transaction, the chief executive officer now owns 55,887 shares of the company’s stock, valued at approximately $13,626,927.21. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Richard S. Levy sold 5,000 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $300.94, for a total value of $1,504,700.00. Following the sale, the director now owns 11,012 shares in the company, valued at $3,313,951.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 22.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC acquired a new stake in Madrigal Pharmaceuticals in the first quarter valued at $102,000. SG Americas Securities LLC bought a new stake in shares of Madrigal Pharmaceuticals in the 1st quarter worth about $360,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Madrigal Pharmaceuticals in the 1st quarter valued at about $326,000. Swiss National Bank raised its stake in shares of Madrigal Pharmaceuticals by 9.3% in the 1st quarter. Swiss National Bank now owns 23,400 shares of the biopharmaceutical company’s stock valued at $6,249,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in Madrigal Pharmaceuticals in the first quarter worth about $584,000. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

Madrigal Pharmaceuticals Company Profile

(Get Free Report)

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.

See Also